| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 1,765 | 1,973 | 28,807 | 560 |
| Cost of revenue | 351 | 326 | 4,716 | 227 |
| Research and development | 17,337 | 18,352 | 18,513 | 19,173 |
| Selling, general and administrative | 11,586 | 9,527 | 15,021 | 15,660 |
| Gain on sale of non-financial asset | 0 | 0 | - | - |
| Total operating expense | -29,274 | -28,205 | -38,250 | -35,060 |
| Loss from operations | -27,509 | -26,232 | -9,443 | -34,500 |
| Interest income | 901 | 665 | 1,025 | 1,871 |
| Interest expense | 2,257 | 2,232 | 2,201 | - |
| Change in fair value of warrant liability | -676 | 2,642 | 10,830 | -1,864 |
| Interest expense | - | - | - | 2,414 |
| Other (expense) income, net | -304 | -547 | 105 | 226 |
| Total other (expense) income, net | -2,336 | 528 | 9,759 | -2,181 |
| (loss) income before provision for income taxes | -29,845 | -25,704 | 316 | -36,681 |
| Provision for income taxes | -30 | 37 | 34 | 15 |
| Net (loss) income | -29,815 | -25,741 | 282 | -36,696 |
| Net loss per share attributable to common stockholdersbasic | -0.69 | -3.47 | 0.04 | -0.18 |
| Net loss per share attributable to common stockholdersdiluted | -0.69 | -3.47 | 0.04 | -0.18 |
| Weighted average shares of common stock outstandingbasic | 43,272,773 | 7,412,990 | 6,840,035 | 200,865,276 |
| Weighted average shares of common stock outstandingdiluted | 43,272,773 | 7,412,990 | 6,869,084 | 200,865,276 |
X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc (XFOR)